Display options
Cite
Ahangarpour A, Heidari H, Fatemeh RA, et al. Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients. J Diabetes Metab Disord. 2014;13(1):29doi: 10.1186/2251-6581-13-29.
Ahangarpour, A., Heidari, H., Fatemeh, R. A., Pakmehr, M., Shahbazian, H., Ahmadi, I., Mombeini, Z., & Mehrangiz, B. H. (2014). Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients. Journal of diabetes and metabolic disorders, 13(1), 29. https://doi.org/10.1186/2251-6581-13-29
Ahangarpour, Akram, et al. "Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients." Journal of diabetes and metabolic disorders vol. 13,1 (2014): 29. doi: https://doi.org/10.1186/2251-6581-13-29
Ahangarpour A, Heidari H, Fatemeh RA, Pakmehr M, Shahbazian H, Ahmadi I, Mombeini Z, Mehrangiz BH. Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients. J Diabetes Metab Disord. 2014 Feb 04;13(1):29. doi: 10.1186/2251-6581-13-29. PMID: 24495344; PMCID: PMC3929136.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab Disord. 2014 Feb 04;13(1):29. doi: 10.1186/2251-6581-13-29.

Effect of Boswellia serrata supplementation on blood lipid, hepatic enzymes and fructosamine levels in type2 diabetic patients.

Journal of diabetes and metabolic disorders

Akram Ahangarpour, Hamid Heidari, Ramezani Ali Akbari Fatemeh, Mostafa Pakmehr, Hajeye Shahbazian, Iraj Ahmadi, Zahra Mombeini, Babadi Hajani Mehrangiz

Affiliations

  1. Department of Physiology, School of Medicine, (Golestan Street), Jundishapur University of Medical Sciences, Ahvaz 61335-189, Iran. [email protected].

PMID: 24495344 PMCID: PMC3929136 DOI: 10.1186/2251-6581-13-29

Abstract

BACKGROUND: Type 2 diabetes is an endocrine disorder that affects a large percentage of patients. High blood glucose causes fatty deposits in the liver which is likely to increase in SGOT and SGPT activities. Significant increase in SGOT/SGPT and low HDL levels is observed in patients with diabetes. Serum fructosamine concentration reflects the degree of blood glucose control in diabetic patients. This study was aimed to investigate the antidiabetic, hypolipidemic and hepatoprotective effects of supplementation of Boswellia serrata in type2 diabetic patients.

METHODS: 60 type 2 diabetic patients from both sexes (30 males and 30 females) were dedicated to the control and intervention groups (30 subjects per group). Boswellia serrata gum resin in amount of 900 mg daily for 6 weeks were orally administered (as three 300 mg doses) in intervention group and the control group did not receive anything. Blood samples were taken at the beginning of the study and after 6 weeks. Blood levels of fructosamine, lipid profiles as well as hepatic enzyme in type 2 diabetic patients were measured.

RESULTS: Treatment of diabetic patient with Boswellia serrata was caused to significant increase in blood HDL levels as well as a remarkable decrease in cholesterol, LDL, fructosamine (p < 0.05) SGPT and SGOT levels after 6 weeks (p < 0.01). In spite of reduction of serum triglyceride, VLDL levels in intervention group, we did not detect a significant difference after 6 weeks.

CONCLUSION: This study showed that Boswellia serrata supplementation can be beneficial in controlling blood parameters in patients with type 2 diabetes. Therefore, its use can be useful in patients with medicines.

References

  1. Diabetes Res. 1991 Dec;18(4):163-8 - PubMed
  2. J Biomed Biotechnol. 2012;2012:902351 - PubMed
  3. Endocrine. 2009 Oct;36(2):268-74 - PubMed
  4. Biochem Pharmacol. 1991 May 15;41(10):1536-7 - PubMed
  5. Food Chem Toxicol. 2011 Oct;49(10):2594-9 - PubMed
  6. Diabetes Care. 2012 Feb;35(2):252-8 - PubMed
  7. Dig Dis Sci. 2012 Aug;57(8):2038-44 - PubMed
  8. Indian J Exp Biol. 2005 Jun;43(6):509-16 - PubMed
  9. J Biol Chem. 1996 May 31;271(22):12964-71 - PubMed
  10. BMC Complement Altern Med. 2009 Mar 25;9:7 - PubMed
  11. J Ethnopharmacol. 2004 Mar;91(1):171-5 - PubMed
  12. J Hepatol. 2004 Apr;40(4):632-7 - PubMed
  13. Indian J Physiol Pharmacol. 2007 Jan-Mar;51(1):29-39 - PubMed
  14. J Diabetes Metab Disord. 2012 Aug 31;11(1):10 - PubMed
  15. J Diabetes Metab Disord. 2012 Oct 17;11(1):20 - PubMed
  16. Pak J Pharm Sci. 2006 Apr;19(2):129-33 - PubMed
  17. Curr Med Chem. 2006;13(28):3359-69 - PubMed
  18. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21 - PubMed
  19. Diabetes Care. 2003 Dec;26(12):3215-8 - PubMed
  20. Agents Actions. 1986 Jun;18(3-4):407-12 - PubMed
  21. Arch Med Res. 2010 May;41(4):302-8 - PubMed

Publication Types